Iron Chelator in Patients with Sickle Cell Anemia, Comparative Study

Abstract

Background: the two main reasons for blood transfusion in sickle cell disease are to correct anemia so that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painful vasoocclusive by lowering the proportion of sickle cell hemoglobin. Iron over load will be evitable.

Objectives: The aim of this study is to asses safety and efficiency of different chelation therapy.

Methodology: Fifty two patients divided in to two equal group, for treatment by combined Deferoxamine-Deferasirox therapy and on Deferasirox alone.

Results: both drug regimens proved to have no adverse effect on hepatic or renal function. The degree of descend of serum ferritin is significantly higher with combined Deferoxamine-Deferasirox therapy.

Conclusion: combined chelating agents have significant effect on serum ferritin, with acceptable level of safety.

Recommendation: combined therapy was safe regime and can be used with good efficacy for patients with iron over load.